Search Results
Your search for Priscilla K. Brastianos, MD matches 9 pages
Showing 1 - 9Vemurafenib Plus Cobimetinib in Newly Diagnosed Patients With Papillary Craniopharyngiomas
In a small phase II trial reported in The New England Journal of Medicine, Priscilla K. Brastianos, MD, and colleagues found that the BRAF-MEK inhibitor combination of vemurafenib and cobimetinib produced an objective response in almost all patients with newly diagnosed papillary craniopharyngiomas ...
Is Pembrolizumab Effective in Patients With Brain Metastases?
In a phase II clinical trial, investigators found that 42% of patients with brain metastases benefited from treatment with the immune checkpoint inhibitor pembrolizumab, with 7 of the 57 patients in the trial surviving for longer than 2 years. The study authors cautioned that these benefits must be ...
Focal Adhesion Kinase Inhibitor in Patients With Meningioma and Somatic NF2 Mutations
As reported in the Journal of Clinical Oncology by Priscilla K. Brastianos, MD, PhD, and colleagues, the phase II Alliance A071401 trial showed activity of the focal adhesion kinase (FAK) inhibitor GSK2256098 in patients with recurrent or progressive grade 1 to 3 meningioma and somatic NF2...
Deciphering the Elusive Origin and Pathways of Brain Metastases
The effective treatment of patients with brain metastases is an unmet need because, until fairly recently, patients with brain metastases were excluded from clinical trials of systemic therapies. However, the emergence of molecular targeted therapies has allowed a new treatment approach in patients ...
Priscilla K. Brastianos, MD, on CNS Metastases: Understanding Their Evolution and the Clinical Implications
Priscilla K. Brastianos, MD, of Harvard Medical School and Massachusetts General Hospital, talks about her efforts to better understand how brain metastases evolve genomically and to test such agents as abemaciclib, paxalisib, and entrectinib, which may stop their growth. Palbociclib, a CDK...
Two Studies Examine the Efficacy of Immunotherapy for Leptomeningeal Carcinomatosis
Two new studies published in Nature Communications indicate that immunotherapy may benefit people with leptomeningeal carcinomatosis, a rare but serious complication of cancer that has spread to the brain and/or spinal cord. Approximately 5% to 8% of all patients with cancer develop leptomeningeal ...
Listen to Conquer Cancer Mini-Podcasts Inspired by StoryCorps and ASCO Members, Grantees
Debuting this year, “Your Stories: Conquering Cancer” are unscripted conversations among doctors, patients, and caregivers who have been affected by cancer. The Conquer Cancer Foundation produced the mini-podcast series through the award-winning StoryCorps organization, a national nonprofit...
Priscilla K. Brastianos, MD, on Genetic Screening of Brain Metastases
Priscilla K. Brastianos, MD, of Massachusetts General Hospital, discusses genomic characterization of brain metastases and paired primary tumors, which could reveal potential therapeutic targets (Abstract 2905).
ASCO Guideline for Management of Brain Metastases From HER2-Positive Breast Cancer: An Important Framework
Brain metastases are a devastating complication of cancer, and occur in up to 50% of patients with advanced human epidermal growth factor 2 (HER2)-positive breast cancer. Management of brain metastases requires individualized coordination between the traditional treatment modalities for...
